We use cookies for a better user experience. Read our Privacy Policy
I Agree
Osteoarthritis Drugs Market
The global osteoarthritis drugs market is expected to reach a market value of about US$ 11,226.1 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Rise in R&D expenditure, increased prevalence of osteoarthritis across the globe, increased geriatric population, rise in awareness regarding degenerative bone diseases in developing countries, and rich pipeline of innovative treatment options are some factors that are expected to boost the global osteoarthritis drugs market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the global osteoarthritis drugs market during the forecast period. However, the high cost of advanced treatments and severe side-effects associated with certain injectable treatments are expected to hamper the osteoarthritis drugs market.
The global osteoarthritis drugs market has been segmented based on drug class, route of administration, and distribution channel. In terms of drug class, the global market has been classified into corticosteroids, NSAIDs & others, and viscosupplementation agents. The viscosupplementation agents segment dominates the global osteoarthritis drugs market, in terms of value, owing to its high cost. This segment is also expected to expand at a significant CAGR owing to its effectiveness in the treatment of knee osteoarthritis, increasing acceptance of viscosupplementation for the treatment of chronic pain associated with osteoarthritis, and long duration of pain relief provided by the treatment. Based on route of administration, the global osteoarthritis drugs market has been divided into oral, parenteral, and topical. The parenteral segment held a major share of the market in 2017. It is expected to maintain its leading position, in terms of market share, during the forecast period.
In terms of distribution channel, the global osteoarthritis drugs market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a major share of the market in 2017, followed by retail pharmacies. The hospital pharmacies segment is expected to maintain its market share during forecast period due to acceptance of advanced treatment options requiring hospitalization. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of over-the-counter drugs at home at a discounted price.
In terms of geography, the global osteoarthritis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global osteoarthritis drugs market owing to high acceptance of viscosupplementation agents in the U.S. and presence of major players in the region. According to the Centers for Disease Control and Prevention, one in every five adults in the U.S. has doctor-diagnosed arthritis. As the country's population ages, it is estimated that this number would increase to at least 67% by 2030. Rising incidence of osteoarthritis leading to disability, demanding advanced therapies and disease modifying drugs, is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure, rising investments in research and development in countries such as China and India, and high acceptance of viscosupplementation agents in Japan. Furthermore, Japan is the second-largest market for viscosupplementation products after the U.S., which in turn is anticipated to further boost the market in Asia Pacific in the near future.
Major players operating in the global osteoarthritis drugs market include Horizon Pharma plc., Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc., Chugai Pharmaceutical Co., Limited, Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.
Osteoarthritis Drugs Market to Rise Remarkably Owing to Increasing Adoption of 3D Printing Technique
Ascend in R&D consumption, expanded commonness of osteoarthritis across the globe, expanded geriatric populace, ascend in mindfulness in regards to degenerative bone illnesses in agricultural nations, and rich pipeline of creative treatment alternatives are a few factors that are relied upon to help the worldwide osteoarthritis drugs market during the conjecture time frame. Additionally, expanding innovative work exercises in sickness changing medications and flood in venture by central participants in the clinical investigations of cutting edge therapy choices are relied upon to impel the worldwide osteoarthritis drugs market during the conjecture time frame. Be that as it may, the significant expense of cutting edge medicines and serious results related with certain injectable medicines are required to hamper the osteoarthritis drugs market.
The developing attention to sicknesses like degenerative bone illness, expanding R&D, and developing geriatric populace are the excellent elements enlarging development of the market. The drug business is developing through an intense stage as a few key licenses have terminated. Then again, the business is additionally confronted with freedoms to decrease fabricating costs impressively, because of headways like 3D printing, a few rewarding reevaluating openings, and possibilities like Nano innovation. This is required to go about as an impetus for advancement in the business with a few firms previously increasing current standards with new medication improvements and crucial adjustments in measures.
Osteoarthritis (OA) is a pervasive sickness all around the world and it influences the older populace harshly. The condition is likewise perilous to numerous as it prompts disabled versatility prompting more possible mishaps and monetary limitations. Be that as it may, the current yield of osteoarthritis drugs just offers torment alleviation and help, yet not a lasting arrangement. Moreover, osteoarthritis drugs likewise neglect to stop infection movement. Henceforth, notwithstanding their absence of adequacy and outrageous significant expenses of viscosupplementation, the worldwide osteoarthritis drugs market keeps on developing. Also, the rising older populace all throughout the planet, and expanding reach of projects like Medicare in the US and privatized medical care bill as of late presented in Australia, the osteoarthritis drugs market will bring about a few new chances for development.
The global osteoarthritis drugs market has been segmented as below:
|
by Drug Class |
|
|
by Route Of Administration |
|
|
by Distribution Channel |
|
|
by Region |
|
Interested in this report?
Get a FREE Brochure now!
*Get Brochure Report (PDF) sent to your email within minutes
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Osteoarthritis Drugs Market
4. Market Overview
4.1. Overview
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2016–2026
4.4.1. Global Osteoarthritis Drugs Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1.Disease Prevalence & Incidence Rate globally with key countries
5.2.Regulatory Scenario by Region/globally
5.3.Pipeline Analysis
6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Corticosteroids
6.3.2. NSAIDs & others
6.3.3. Viscosupplementation Agents
6.4. Global Osteoarthritis Drugs Market Attractiveness by Drug Class
7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration
8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospital pharmacies
8.3.2. Retail pharmacies
8.3.3. Online pharmacies
8.4. Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel
9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Osteoarthritis Drugs Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Osteoarthritis Drugs Market Attractiveness, by Region
10. North America Osteoarthritis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. North America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
10.2.1.Corticosteroids
10.2.2. NSAIDs & Others
10.2.3.Viscosupplementation agents
10.3. North America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. North America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital pharmacies
10.4.2. Retail pharmacies
10.4.3. Online pharmacies
10.5. North America Osteoarthritis Drugs Market Value Forecast, by Country, 2016–2026
10.5.1. US
10.5.2. Canada
10.6. North America Osteoarthritis Drugs Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Osteoarthritis Drugs Market Analysis and Forecast
11.1.Introduction
11.2. Europe Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Corticosteroids
11.2.2. NSAIDs & Others
11.2.3. Viscosupplementation agents
11.3. Europe Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Europe Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital pharmacies
11.4.2. Retail pharmacies
11.4.3. Online pharmacies
11.5. Europe Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. France
11.5.3. U.K.
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Osteoarthritis Drugs Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
12.1.Introduction
12.2. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Corticosteroids
12.2.2. NSAIDs & Others
12.2.3. Viscosupplementation agents
12.3. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital pharmacies
12.4.2. Retail pharmacies
12.4.3. Online pharmacies
12.5. Asia Pacific Osteoarthritis Drugs Market Value Forecast by Country/Sub-region, 2016–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
13.1.Introduction
13.2. Latin America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Corticosteroids
13.2.2. NSAIDs & Others
13.2.3. Viscosupplementation agents
13.3. Latin America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Latin America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital pharmacies
13.4.2. Retail pharmacies
13.4.3. Online pharmacies
13.5. Latin America Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Osteoarthritis Drugs Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
14.1.Introduction
14.2. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
14.2.1. Corticosteroids
14.2.2. NSAIDs & Others
14.2.3. Viscosupplementation agents
14.3. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Topical
14.4. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital pharmacies
14.4.2. Retail pharmacies
14.4.3. Online pharmacies
14.5. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Country/Sub-regions, 2016–2026
14.5.1. GCC Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1. Global Osteoarthritis Drugs Market Player – Competition Matrix (by Tier and Size of companies)
15.2. Global Osteoarthritis Drugs Market Share Analysis, by Company (2016)
15.3. Company Profiles
15.3.1. Horizon Pharma plc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Anika Therapeutics, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ferring B.V.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bioventus, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Chugai Pharmaceutical Industries Limited
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Alkem Laboratories
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Flexion Therapeutics, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Zimmer Biomet Holdings, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 03: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 06: North America Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 07: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 09: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 10: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 11: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 12: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 13: Asia Pacific Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 14: Asia Pacific Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 15: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 18: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 19: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 20: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Middle East & Africa Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 24: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
List of Figures
Figure 01: Global Osteoarthritis Drugs Market Snapshot
Figure 02: Global Fluid Management Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 03: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, 2016?2026
Figure 04: Global Osteoarthritis Drugs Market Value Share, by Drug Class (2017)
Figure 05: Global Osteoarthritis Drugs Market Value Share, by Route of Administration (2017)
Figure 06: Global Osteoarthritis Drugs Market Value Share, by Distribution Channel (2017)
Figure 07: Global Osteoarthritis Drugs Market Value Share, by Region (2017)
Figure 08: Global Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 09: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids
Figure 10: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Others
Figure 11: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Viscosupplementation Agents
Figure 12: Global Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 13: Global Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 14: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2016–2026
Figure 15: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2016–2026
Figure 16: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2016–2026
Figure 17: Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 18: Global Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 19: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 20: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 21: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2016–2026
Figure 22: Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 23: Global Osteoarthritis Drugs Market Value Share Analysis, by Region 2017 and 2026
Figure 24: Global Osteoarthritis Drugs Market Attractiveness, by Region, 2018–2026
Figure 25: North America Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: North America Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 27: North America Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 28: North America Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 29: North America Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 30: North America Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 31: North America Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 32: North America Osteoarthritis Drugs Market Value Share (%), by Country, 2017 and 2026
Figure 33: North America Osteoarthritis Drugs Market Attractiveness, by Country, 2018–2026
Figure 34: Europe Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 35: Europe Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 36: Europe Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 37: Europe Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 38: Europe Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 39: Europe Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 40: Europe Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 41: Europe Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 42: Europe Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 43: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 44: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 45: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 46: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 47: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 48: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 49: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 50: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 51: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 52: Latin America Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 53: Latin America Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 54: Latin America Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 55: Latin America Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 56: Latin America Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 57: Latin America Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 58: Latin America Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 59: Latin America Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 60: Latin America Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 61: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 62: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 63: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 64: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 65: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 66: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 67: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 68: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 69: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 70: Global Osteoarthritis Drugs Market Share Analysis, by Company (2017)
Figure 71: Horizon Pharma plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 72: Horizon Pharma plc. Breakdown of Net Sales, by Region, 2017
Figure 73: Horizon Pharma plc. Breakdown of Net Sales, by Drug, 2017
Figure 74: Horizon Pharma plc. Research & Development Cost (US$ Mn), 2015–2017
Figure 75: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 76: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
Figure 77: Sanofi Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 78: Sanofi Breakdown of Net Sales, by Region, 2017
Figure 79: Sanofi Breakdown of Net Sales, by Business Segment, 2017
Figure 80: Sanofi Research & Development Cost, 2015–2017 (US$ Mn)
Figure 81: Anika Therapeutics, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 82: Anika Therapeutics, Inc. Breakdown of Net Sales, by Region, 2017
Figure 83: Anika Therapeutics, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 84: Anika Therapeutics, Inc. Research & Development Cost, 2015–2017 (US$ Mn)
Figure 85: Chugai Pharmaceutical Co., Limited. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 86: Chugai Pharmaceutical Co., Limited. Breakdown of Net Sales, by Region, 2017
Figure 87: Chugai Pharmaceutical Co., Limited. Breakdown of Net Sales, by Business Segment, 2017
Figure 88: Chugai Pharmaceutical Co., Limited. Research & Development Cost (US$ Mn), 2015–2017
Figure 89: Alkem Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 90: Alkem Laboratories Breakdown of Net Sales, by Region, 2017
Figure 91: Alkem Laboratories Breakdown of Net Sales, by Business Segment, 2017
Figure 92: Alkem Laboratories Research & Development Cost (US$ Mn), 2015–2017
Figure 93: Zimmer Biomet Holdings, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 94: Zimmer Biomet Holdings, Inc. Breakdown of Net Sales, by Region, 2017
Figure 95: Zimmer Biomet Holdings, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 96: Zimmer Biomet Holdings, Inc. Research & Development Cost (US$ Mn), 2015–2017
Complete the form below and we'll get back to you shortly.
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
